From lyophilized bulk API to a sterile vial, under a defensible framework.

Defining the finished product

Before any formulation work begins, the target product profile must be locked: peptide mass per vial, fill volume prior to lyophilization, intended reconstitution volume, concentration after reconstitution, single- vs multi-dose presentation, storage class (2–8 °C or frozen), required shelf life, and product status (research use, investigational medicinal product or finished medicinal product). Without these inputs no formulation can be developed in a defensible way.

Incoming API control

The supplied peptide bulk is qualified against a defined panel: identity, assay and purity, counterion (acetate, trifluoroacetate, hydrochloride), residual moisture, residual solvents, related substances, aggregation, bioburden, bacterial endotoxins, and — where relevant — sterility. A vendor CoA stating "99 % purity" is not sufficient for a sterile injectable. A 0.22 µm sterilizing filter removes microorganisms but does not reliably remove endotoxins already present, so endotoxin burden must be controlled at the API stage.

Anchor · EU GMP Annex 1 (2022): contamination control strategy

Formulation development with excipients

The API is not simply dissolved in water. A formulation is developed that protects the peptide during freezing, drying, storage and reconstitution. Excipient selection is sequence-dependent — solubility, oxidation susceptibility, aggregation propensity, pH sensitivity and surface adsorption all dictate which functions are required. The matrix below lists representative excipient classes, not a recipe.

Anchor · ICH Q8 (R2): pharmaceutical development & CQAs

Formulation screening

Multiple formulation variants are screened at small scale across pH, buffer system, sugar / bulking agent, peptide concentration, freezing protocol, in-solution hold time and light/oxygen exposure. Purity, aggregation, solubility and — where defined — biological activity are compared. A peptide can degrade measurably during the hold time in solution before lyophilization; ICH Q8 explicitly calls for the control of in-solution degradation prior to freeze drying.

Primary packaging preparation

Glass vials are washed and depyrogenized; elastomeric stoppers are cleaned and sterilized; aluminum overseals are prepared; product-contact components are sterilized or deployed as single-use sterile assemblies. Processing occurs in a qualified cleanroom, RABS or isolator environment. Vial glass type, stopper formulation and silicone treatment must be confirmed compatible with the peptide.

Compounding the bulk solution

The bulk API is dissolved in Water for Injection (WFI) under controlled conditions: buffer and excipients first, peptide added in a controlled manner, gentle mixing to avoid shear and foam, pH verification and adjustment, top-up to target volume, in-process concentration and appearance checks, and adherence to a defined maximum hold time before filtration. Light protection, low temperature, nitrogen blanketing or hypoxic processing are deployed where the sequence demands it.

Sterile filtration

Where filterable, the solution is passed through a validated 0.22 µm sterilizing-grade filter. Validation covers filter–product compatibility, peptide adsorption losses, pre-filtration bioburden, pre- and post-use integrity (bubble point / pressure hold), maximum filtration time, transmembrane pressure, flow rate, and post-filtration hold. Where terminal sterilization is precluded by thermal lability, the rationale for an aseptic-only strategy must be documented — the EMA decision tree requires a scientific justification for the chosen sterilization approach.

Aseptic fill & finish

The sterile solution is dosed into vials under aseptic conditions: controlled fill volume, in-process fill-weight checks, partial stoppering with lyophilization stoppers, and transfer of the partially closed vials into the lyophilizer. The vials remain only partially closed so that water vapor can escape during drying.

Lyophilization in the final vial

The cycle comprises three phases. Freezing — the solution is cooled in a controlled fashion, generating ice and a concentrated freeze-concentrate. Primary drying — under vacuum, ice sublimates directly to vapor; shelf temperature and chamber pressure are held below the formulation's collapse temperature. Secondary drying — more strongly bound residual water is removed by desorption to a defined residual moisture target. Each phase is monitored against product temperature, chamber pressure and (where instrumented) Pirani/capacitance manometer ratio for endpoint detection.

Anchor · FDA, Guide to Inspections of Lyophilization of Parenterals (1993)

Stoppering & crimping

At the end of the cycle, stoppers are seated fully inside the closed lyophilizer — under vacuum, under nitrogen or under a defined inert atmosphere, depending on product sensitivity. Vials are then transferred out and crimped with aluminum overseals. Container–closure integrity is verified as part of release testing.

Finished-product testing

A product-specific subset of: cake appearance, content / fill-weight uniformity, identity, peptide assay, purity and related substances, biological activity where applicable, residual moisture, reconstitution time, post-reconstitution pH and osmolality, visible particles, sub-visible particulates, sterility, bacterial endotoxins, container–closure integrity, residual solvents, and overall filter / process yield.

Anchor · USP <1207> Container–Closure Integrity

Stability studies & batch release

Shelf life is established only on stability data — long-term, accelerated, and, where justified, stress conditions, plus in-use stability after reconstitution and temperature-excursion / transport studies. For biotech-derived products, ICH Q5C requires that stability protocols address physicochemical properties, purity, biological activity and microbiological attributes, and consider potential excipient degradation and interaction.

Anchor · ICH Q5C / ICH Q1A (R2)